Financial Report: Merck

Merck
 
3Q Revenues: $11.0 billion (-4%)

3Q Earnings: $1.1 billion (-35%)

YTD Revenues: $32.7 billion (-8%)

YTD Earnings: $3.7 billion (-31%)

Comments: Pharmaceutical sales were down 4% to $9.5 billion in the quarter, impacted by a 2% negative impact due to foreign exchange and loss of exclusivity for Singulair (-53% to $280 million), Maxalt (-76% to $40 million), Temodar (-29% to $162 million) and Cozaar/Hyzaar (-20% to $238 million). Remicade sales were up 17% to $574 million. Gardasil sales were up 15% to $665 million. Simponi sales were up 47% to $126 million. Isentress sales were up 7% to $427 million. Animal Health sales totaled $800 million in the quarter, down 2% and Consumer Care sales were $443 million, down 2%.